Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8642584 Method of using PI3K and MEK modulators

Patent 8642584 was granted and assigned to Exelixis on February, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Exelixis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

86425840

Patent Inventor Names

Jean-Francois A. Martini0

A. Douglas Laird0

Dana T. Aftab0

Peter Lamb0

Date of Patent

February 4, 2014

Patent Application Number

135686490

Date Filed

August 7, 2012

Patent Citations Received

‌

US Patent 12089588 Reduction of erythrocyte sedimentation rate

‌

US Patent 12121022 Stabilization of thrombocytes at ambient temperatures

‌

US Patent 11672247 Stabilization of thrombocytes at ambient temperatures

Patent Primary Examiner

‌

Dennis Heyer

Patent abstract

The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8642584 Method of using PI3K and MEK modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API